Non–Small Cell Lung Cancer Coverage from Every Angle

C. Jillian Tsai, MD, PhD, on Using Stereotactic Body Radiotherapy to Reduce Oligoprogression in Advanced Lung Cancer

Posted: Tuesday, November 2, 2021

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the CURB study, which suggests that adding stereotactic body radiation therapy to the drug regimen for patients with oligoprogressive, metastatic lung cancer may improve progression-free survival.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.